Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice
about
International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease statesBombesin-related peptides and their receptors: recent advances in their role in physiology and disease statesBombesin receptor-mediated imaging and cytotoxicity: review and current statusIn vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues.Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.Radiolabeled bombesin derivatives for preclinical oncological imaging.Radiometallated peptides for molecular imaging and targeted therapy.In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.A fast tumor-targeting near-infrared fluorescent probe based on bombesin analog for in vivo tumor imaging.A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer.Near-infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases.Early over-expression of GRP receptors in prostatic carcinogenesis.Impact of dianionic and dicationic linkers on tumor uptake and biodistribution of [64 Cu]Cu/NOTA peptide-based gastrin-releasing peptide receptors antagonists.
P2860
Q24643524-1B988882-A50E-43AC-9D3A-F3C6107B2B3FQ24645097-3A398492-7DC2-4ABC-9876-7692E0C5922FQ34684387-DDD2B704-3447-44B9-9DC0-160BC150DC68Q34942281-38669FC5-CDD2-4E77-8FAC-1708C254303AQ35925945-0A1DC6D3-D3F6-46B9-AC8B-1B147E33FECDQ36338484-20AD7CB6-4F55-4BB8-BA4D-0ED48F661832Q37109589-96FB389A-5904-4941-973F-ED96E2AAE57AQ37674035-5CE6B678-3E5D-4480-B942-76BF9C3D9168Q37847064-63D94152-DCD7-4D82-80E6-5708328A1B00Q38925590-C477733C-4F4D-45C9-97F4-7B3ABE39980CQ39024393-33A5A3B9-F029-40CD-AAEA-CAD778E930A8Q39066397-BBAC855F-5CE3-434F-884E-2666EC3BF3FDQ39218047-2046A09A-EA99-47A0-8516-A3629994F1D9Q46266299-1F121C65-7FDF-407A-8146-361682FB41DAQ48303231-51CE8C72-DAEE-4090-9B22-FF9F3B538515
P2860
Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of combined (177)Lu ...... mor cell xenografted SCID mice
@en
Evaluation of combined
@nl
type
label
Evaluation of combined (177)Lu ...... mor cell xenografted SCID mice
@en
Evaluation of combined
@nl
prefLabel
Evaluation of combined (177)Lu ...... mor cell xenografted SCID mice
@en
Evaluation of combined
@nl
P2093
P2860
P356
P1476
Evaluation of combined (177)Lu ...... mor cell xenografted SCID mice
@en
P2093
Charles J Smith
Christopher V Johnson
Michael C Perry
Tiffani Shelton
Timothy J Hoffman
Wynn A Volkert
P2860
P304
P356
10.1089/CBR.2006.21.155
P577
2006-04-01T00:00:00Z